Ciba Expands Deal With Isis On Antisense
Ciba has reinforced its commitment to antisense research by significantly expanding its five-year-old agreement with Isis Pharmaceuticals to include a broader program of anticancer research.
Under the terms of the new agreement, Isis will continue its antisense drug discovery efforts to the specific molecular targets selected by the two firms, with appropriate funding from Ciba. Specifically, Ciba will continue to fund the ongoing protein kinase C (PKC) inhibitor project, including the lead PKC-alpha inhibitor, ISIS 3521/CGP 64128A, and other therapeutics targeting PKC isotypes. ISIS 3521 entered Phase I trials in January.
Ciba will also support the development of ISIS 5132/CGP 68846A, an antisense inhibitor of c raf-kinase (a member of a multigene family of signal transduction proteins associated with abnormal cell growth), as well as follow-up compounds. Isis says it plans to file an Investigational New Drug Application for ISIS 3521 before the end of the month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze